Clinical Trial

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of VX-407 in healthy participants.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-06-06; most recent amendment 2026-03-25.
Status change: Active, Not Recruiting → Completed 2026-03-25
Status change: Recruiting → Active, Not Recruiting 2026-02-27
Status change: Completed → Recruiting 2025-11-18
Status change: Recruiting → Completed 2025-10-09
Status change: Not Yet Recruiting → Recruiting 2025-07-09
Trial Details
NCT Number NCT07022119
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Enrollment 32 participants
Start Date 2025-06-12
Primary Completion 2026-02-24 (estimated)
Study Completion 2026-02-24 (estimated)
Updated on ClinicalTrials.gov 2026-03-27